COGNY yields 4.85% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, COGNY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of COGNY + PFE for your $10,000?
Cogna Educação S.A. operates as a private educational organization in Brazil and internationally. The company operates through three segments: In-Class Higher Education, Distance Learning Higher Education, and Basic Education. It offers in-class and distance-learning higher education, and undergraduate and graduate courses; publishes, sells, and distributes textbooks, support materials, and workbooks with educational, literary, and informative content and teaching systems; and educational solutions for professional and higher education, and other supplementary activities, such as developing education technology with management and other education services. The company also provides K-12 education, pre-college preparatory, language courses for children and teenagers; management of child, primary, and secondary education activities; technical and preparatory courses for civil service examinations and Brazilian Bar Association; advises on and/or facilitates direct and indirect student loans; and develops software for adaptive teaching and academic management optimization. Its services include primary, secondary, and postsecondary education services with on-campus undergraduate and graduate programs, and distance learning, as well as graduate programs; preparatory courses under the brand LFG; and unregulated programs. The company operates 176 college education units in 24 Brazilian states and 132 Brazilian cities; and 1,510 distance-learning graduation centers in various Brazilian states and in the Federal District, as well as operates 54 own K-12 education schools, 125 Red Balloon units, and approximately 5,600 associated schools in Brazil. Cogna Educação S.A. was founded in 1998 and is headquartered in Belo Horizonte, Brazil.
Full COGNY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.